12:00 AM
 | 
Jan 03, 2011
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Acetylon preclinical data

In mouse xenograft models of MM, daily ACY-1215 plus once- or twice-weekly Velcade bortezomib significantly inhibited tumor growth and prolonged survival vs. controls (p<0.001 for both). ACY-1215 is an oral...

Read the full 138 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >